Module 6. Monitoring and Evaluation (M&E)

Session 2. Measuring NTDP Performance
Objectives

By the end of this session, participants should:

• Understand the rationale for monitoring NTDP activities and key process indicators
• Define and calculate treatment coverage rates
• List attributes of a good data collection system
• Be prepared to make decisions and take action based on M&E findings
Measures During MDA Management Phase

Key M&E Indicators

- Process/performance indicators
- Drug efficacy
- Number of SAEs
- Reported Treatment Coverage
- Survey Coverage
- Data quality indicators

Managing MDAs

- Planning
- Drug management
- Data management system
- Social mobilization, advocacy, IEC materials
- Training & supervision
- MDA implementation

Setting Up

- PC safety

Surveillance

- Surveillance
- Planning
- Drug management
- Data management system

Module 6. Monitoring and Evaluation (M&E)
Session 2. Measuring NTDP Performance
MEASURING ACTIVITIES
<table>
<thead>
<tr>
<th>INPUTS</th>
<th>ACTIVITIES</th>
<th>OUTPUTS</th>
<th>OUTCOMES</th>
<th>IMPACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>What we invest</td>
<td>What we do</td>
<td>The results</td>
<td>Short term</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Long term</td>
</tr>
</tbody>
</table>

**Module 6. Monitoring and Evaluation (M&E)**

**Session 2. Measuring NTDP Performance**
Module 6. Monitoring and Evaluation (M&E)
Session 2. Measuring NTDP Performance

Do we have on board everything that we need?
NTDP Program Activities

- # of social mobilization meetings held at national/district level
- # of coordination meetings held at national/district level
- Master Plan and annual work plans completed
- # of IEC materials developed, produced, and distributed
- # training sessions held, # of CDDs/HWs trained
- # of CDDs/HWs who took part in PC
MEASURING OUTCOMES
<table>
<thead>
<tr>
<th>INPUTS</th>
<th>ACTIVITIES</th>
<th>OUTPUTS</th>
<th>OUTCOMES</th>
<th>IMPACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>What we invest</td>
<td>What we do</td>
<td>The results</td>
<td>Short term</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Long term</td>
<td></td>
</tr>
</tbody>
</table>

Module 6. Monitoring and Evaluation (M&E)
Session 2. Measuring NTDP Performance
How Do We Know That We Are Going in the Right Direction?

I see those strange rock formations ... we must be going the right way.
KEY MEASURE = TREATMENT COVERAGE
## Types of Coverage

<table>
<thead>
<tr>
<th>Geographical coverage</th>
<th>National coverage</th>
<th>Therapeutic or Epidemiological coverage</th>
<th>Programme coverage</th>
<th>Surveyed coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of endemic IU’s where PC is implemented</td>
<td>Number of individuals ingesting the PC medicines in an endemic country</td>
<td>Number of individuals ingesting the PC medicines at IU level for a specific disease</td>
<td>Number of individuals ingesting the PC medicines</td>
<td>Number of surveyed individuals who report ingesting the PC medicines</td>
</tr>
<tr>
<td>Number of endemic IU’s where PC is required</td>
<td>Number of individuals at national level requiring PC in an endemic country</td>
<td>Number of individuals at IU level requiring PC in an endemic IU</td>
<td>All the individuals targeted for treatment</td>
<td>Number of persons surveyed</td>
</tr>
</tbody>
</table>

Number of individuals ingesting the PC medicines x 100

Number of individuals ingesting the PC medicines at IU level for a specific disease x 100

Number of individuals at IU level requiring PC in an endemic IU x 100

All the individuals targeted for treatment x 100

Number of persons surveyed x 100
The Building Blocks of Coverage

Numerator (treated)
- IUs where PC is implemented
- Individuals ingesting treatment

Types of Coverage
- Geographical coverage
- National coverage
- Therapeutic/Epi coverage
- Programme coverage

Denominator (population)
- Endemic IUs
- Individuals requiring PC (includes non-eligible populations. They require treatment although it is contraindicated for them.)
  - National level
  - IU level
- Individuals targeted by program

Numerator
- IUs where PC is implemented

Denominator
- Population

Geographical coverage
- National
- Therapeutic/Epi
- Programme

Individuals requiring PC
- National level
- IU level
The Different Coverage Rates Answer Different Questions …

<table>
<thead>
<tr>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the programme reach its targeted population?</td>
</tr>
<tr>
<td>What progress have I made towards my control/elimination goals at <strong>IU level</strong>?</td>
</tr>
<tr>
<td>What progress have I made towards my control/elimination goals at <strong>national level</strong>?</td>
</tr>
<tr>
<td>How close am I to fully scaling up the programme?</td>
</tr>
</tbody>
</table>
EXAMPLES
Results of Mapping

Endemicity maps

- LF
- STH
What Is Your Treatment Strategy?

- treat >2 yrs old in districts A, B, and E
- treat all SAC in all districts (1 x per year)
What Is Your Treatment Strategy?

- Treat >2 yrs old in districts A, B, and E
- Treat all SAC in all districts (1 x per year)
What If You Only Had Funding to Treat A, B, C and E?

Endemicity maps

Treatment strategy

ALB + DEC for eligible population in A, B and E

ALB for SAC in C, D and F

What If You Only Had Funding to Treat A, B, C and E?
What’s the GEOGRAPHICAL Coverage for LF?

Geographical coverage

\[
\text{Number of endemic administrative units where PC is implemented} \times 100 \quad \frac{\text{Number of endemic administrative units where PC is required}}{3} \times 100 = 100\%
\]

Endemicity maps

Treatment strategy

ALB + DEC for eligible population in A, B and E

ALB for SAC in C, D and F
What’s the GEOGRAPHICAL Coverage for STH?

<table>
<thead>
<tr>
<th>LF</th>
<th>Geographical coverage</th>
<th>STH</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\frac{3}{3} \times 100 = 100%$</td>
<td>Number of endemic administrative units where PC is implemented</td>
<td>$\frac{4}{6} \times 100 = 67%$</td>
</tr>
</tbody>
</table>

Endemicity maps

Treatment strategy

ALB + DEC for eligible population in A, B and E

ALB for SAC in C, D and F
Let’s Focus on District A

(Remember: A is endemic for LF and STH)
Population and Treatment Data for A for LF (For ALB+DEC Distribution)

POPULATION DATA
100 persons total
40 SAC
10 <2 years

TREATED (MDA RESULTS)
60 persons treated total
30 SAC treated
How Well Did the Programme Reach Target for LF?

Programme coverage

\[
\text{Programme coverage} = \frac{\text{Number of individuals ingesting the PC medicines in endemic administrative unit(s)}}{\text{All the individuals targeted for treatment in endemic administrative unit(s)}} \times 100
\]

POPULATION DATA
100 persons total
40 SAC
10 <2 years

TREATED (MDA RESULTS)
60 persons treated total
30 SAC treated

\[
\text{LF} = \frac{60}{90} \times 100 = 67\%
\]

<2 excluded from treatment so all individuals targeted for treatment = 100 - 10 = 90
How Close Are We to the Elimination Goals for LF?

**Therapeutic or Epidemiological coverage**

\[
\frac{\text{Number of individuals ingesting the PC medicines at IU level for a specific disease}}{\text{Total population of an IU}} \times 100
\]

**POPULATION DATA**
- 100 persons total
- 40 SAC
- 10 <2 years

**TREATED (MDA RESULTS)**
- 60 persons treated total
- 30 SAC treated

\[
\frac{60}{100} \times 100 = 60\%
\]
## Review of Coverage for LF

### Programme coverage

\[
\text{Programme coverage} = \frac{\text{Number of individuals ingesting the PC medicines in endemic administrative unit(s)}}{\text{All the individuals targeted for treatment in endemic administrative unit(s)}} \times 100
\]

| LF | \[
\frac{60}{90} \times 100 = 67\%
\]

### Therapeutic or Epidemiological coverage

\[
\text{Therapeutic or Epidemiological coverage} = \frac{\text{Number of individuals ingesting the PC medicines at IU level for a specific disease}}{\text{Total population of an IU}} \times 100
\]

| LF | \[
\frac{60}{100} \times 100 = 60\%
\]

### Have you reached your benchmark for LF? (therapeutic or epidemiological coverage)

Benchmark for LF = 65%

No Benchmark not reached for LF
Returning to the Map of All Regions...

Focus on C

Treatment strategy

ALB + DEC for eligible population in A, B and E
ALB for SAC in C, D and F

Endemicity maps
Returning to the Map of All Regions ...

Focus on C
Data for C
(Treatment for STH Only)

Total population: 1,000
School-based treatment
Total schools: 40
SAC population: 400
Due to funding limitations, only
20 schools (200 SAC total) were targeted
160 SAC were actually treated
What’s the PROGRAMME COVERAGE for C for STH?

Total population: 1,000
School-based treatment
Total schools: 40
SAC population: 400

Due to funding limitations, only 20 schools (200 SAC total) were targeted. 160 SAC were actually treated.

<table>
<thead>
<tr>
<th>Programme coverage</th>
<th>STH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of individuals ingesting the PC medicines in endemic administrative unit(s) x 100</td>
<td>160 x 100 = 80%</td>
</tr>
<tr>
<td>All the individuals targeted for treatment in endemic administrative unit(s)</td>
<td>200</td>
</tr>
</tbody>
</table>

Programme coverage calculation:

\[
\text{Coverage} = \left( \frac{\text{Actual SAC treated}}{\text{Targeted SAC}} \right) \times 100 = \left( \frac{160}{200} \right) \times 100 = 80\%
\]
What’s the THERAPEUTIC or EPIDEMIOLOGICAL Coverage for C for STH?

Total population: 1,000
School-based treatment
Total schools: 40
SAC population: 400

Due to funding limitations, only 20 schools (200 SAC total) were targeted
160 SAC were actually treated

Programme coverage
Number of individuals ingesting the PC medicines in endemic administrative unit(s) \( \times \) 100

\[
\text{All the individuals targeted for treatment in endemic administrative unit(s)}
\]

\[
\frac{160}{200} \times 100 = 80\%
\]

Therapeutic or Epidemiological coverage
Number of individuals ingesting the PC medicines at IU level for a specific disease \( \times \) 100

\[
\text{Total population of an IU}
\]

\[
\frac{160}{400} \times 100 = 40\%
\]
How Well Did You Do in Reaching the Population You Set Out to Treat?

Total population: 1,000

School-based treatment
Total schools: 40
SAC population: 400

Due to funding limitations, only 20 schools (200 SAC total) were targeted, 160 SAC were actually treated.

- **Programme coverage**
  - Number of individuals ingesting the PC medicines in endemic administrative unit(s) x 100
  - All the individuals targeted for treatment in endemic administrative unit(s)
  - Programme coverage helps us answer this question
  - STH
    - \[ \frac{160}{200} \times 100 = 80\% \]

- **Therapeutic or Epidemiological coverage**
  - Number of individuals ingesting the PC medicines at IU level for a specific disease x 100
  - Total population of an IU
  - STH
    - \[ \frac{160}{400} \times 100 = 40\% \]
Of All the Persons Needing Treatment How Well Did You Do?

Total population: 1,000

School-based treatment
Total schools: 40
SAC population: 400

Due to funding limitations, only 20 schools (200 SAC total) were targeted.
160 SAC were actually treated

**Programme coverage**

Number of individuals ingesting the PC medicines in endemic administrative unit(s) \( \times \) 100

\[
\text{All the individuals targeted for treatment in endemic administrative unit(s)}
\]

**Therapeutic or Epidemiological coverage**

Number of individuals ingesting the PC medicines at IU level for a specific disease \( \times \) 100

\[
\text{Total population of an IU}
\]

Therapeutic/epi coverage helps us answer this question

\[
\frac{160}{200} \times 100 = 80\%
\]

\[
\frac{160}{400} \times 100 = 40\%
\]
Returning to the Map of All Regions...

Treatment strategy

ALB for SAC in C, D and F

ALB + DEC for eligible population in A, B and E

Returning to the Map of All Regions…

Module 6. Monitoring and Evaluation (M&E)
Session 2. Measuring NTDP Performance
### National Data for LF

<table>
<thead>
<tr>
<th></th>
<th>Total Population</th>
<th>Eligible Population</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>100</td>
<td>90</td>
<td>60</td>
</tr>
<tr>
<td>B</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
<tr>
<td>E</td>
<td>100</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>C</td>
<td>100 (not endemic)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>D</td>
<td>100 (not endemic)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F</td>
<td>100 (not endemic)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**What’s the NATIONAL COVERAGE for LF?**

\[
\text{Number of individuals ingesting the PC medicines for a specific disease in an endemic country} \times \frac{\text{Number of individuals at national level requiring PC for a specific disease in an endemic country}}{100} = 85\% \times 100
\]

\[
\frac{230}{270} \times 100 = 85\%
\]
### National Data for LF

<table>
<thead>
<tr>
<th></th>
<th>Total Population</th>
<th>Eligible Population</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>100</td>
<td>90</td>
<td>60</td>
</tr>
<tr>
<td>B</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
<tr>
<td>C</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
<tr>
<td>D</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
<tr>
<td>E</td>
<td>100</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>F</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
</tbody>
</table>

**What’s the NATIONAL COVERAGE for LF?**

\[
\text{Number of individuals ingesting the PC medicines for a specific disease in an endemic country} \times 100 \div \text{Number of individuals at national level requiring PC for a specific disease in an endemic country} = 85\%
\]

Number of individuals ingesting the PC medicines for a specific disease in an endemic country

Number of individuals at national level requiring PC for a specific disease in an endemic country

\[
\begin{align*}
\text{Total} & = 230 \\
\text{Required} & = 270 \\
\end{align*}
\]

\[
\frac{230}{270} \times 100 = 85\%
\]

**What’s the GEOGRAPHICAL COVERAGE for LF?**

\[
\text{Number of endemic administrative units where PC is implemented} \times 100 \div \text{Number of endemic administrative units where PC is required} = 100\%
\]

Number of endemic administrative units where PC is implemented

Number of endemic administrative units where PC is required

\[
\begin{align*}
\text{Implemented} & = 3 \\
\text{Required} & = 3 \\
\end{align*}
\]

\[
\frac{3}{3} \times 100 = 100\%
\]
National Data for LF

<table>
<thead>
<tr>
<th></th>
<th>Total Population</th>
<th>Eligible Population</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>100</td>
<td>90</td>
<td>60</td>
</tr>
<tr>
<td>B</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
<tr>
<td>E</td>
<td>100</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>C</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
<tr>
<td>D</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
<tr>
<td>F</td>
<td>100</td>
<td>(not endemic)</td>
<td>0</td>
</tr>
</tbody>
</table>

**What’s the NATIONAL COVERAGE for LF?**

\[
\text{NATIONAL COVERAGE} = \left( \frac{\text{Number of individuals ingesting the PC medicines for a specific disease in an endemic country}}{\text{Number of individuals at national level requiring PC for a specific disease in an endemic country}} \right) \times 100
\]

\[
230 \times 100 = 85\%
\]

**What’s the GEOGRAPHICAL COVERAGE for LF?**

\[
\text{GEOGRAPHICAL COVERAGE} = \left( \frac{\text{Number of endemic administrative units where PC is implemented}}{\text{Number of endemic administrative units where PC is required}} \right) \times 100
\]

\[
3 \times 100 = 100\%
\]
### Which Type of Coverage Answers Each Question?

<table>
<thead>
<tr>
<th>Question</th>
<th>Coverage Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the program reach its targeted population?</td>
<td>Programme coverage</td>
</tr>
<tr>
<td>Have I made progress towards my control/elimination goals at IU/district level?</td>
<td>Therapeutic/Epi coverage</td>
</tr>
<tr>
<td>Have I made progress towards my control/elimination goals at national level?</td>
<td>National coverage</td>
</tr>
<tr>
<td>How close am I to full scale-up?</td>
<td>Geographical coverage</td>
</tr>
</tbody>
</table>

**Examples:**

- **Programme coverage**
  - Did the program reach its targeted population?

- **Therapeutic/Epi coverage**
  - Have I made progress towards my control/elimination goals at IU/district level?

- **National coverage**
  - Have I made progress towards my control/elimination goals at national level?

- **Geographical coverage**
  - How close am I to full scale-up?
Exercise

• Using the data provided calculate the following for LF and STH treatments.
  – Programme Coverage (at district level)
  – National Coverage (at country level)
  – Geographical Coverage (at country level)
  – District Coverage (at district level) – LF only
What is this data telling you as programme manager?

What actions would you take next?
COVERAGE ESTIMATES ARE IMPORTANT FOR MAKING DECISIONS, BUT THEY ARE ONLY AS GOOD AS THE DATA USED TO CALCULATE THEM
How does NTD data on numbers treated flow in your country?

Draw a diagram of the data-flow.
Recommended Pathway for Preventive Chemotherapy Data Flow

- **Periphera l Treatment Records**
  - Household
  - School
  - Village
  - Community
  - Other (e.g., health centre)

- **Sub-District Levels**
  - Round 1: Complete data compilation form after every treatment round
  - Round 2: Complete data compilation form after every treatment round

- **District Summary**
  - Compiled after every treatment round
  - Must monitor completeness of reports after every treatment round

- **National Summary**
  - Compiled after every treatment round
  - Submitted to WHO annually

**Data Flow**

- Baseline level: compiled after every round of preventive chemotherapy
- Mid-level
- National level

---

Module 6. Monitoring and Evaluation (M&E)
Session 2. Measuring NTDP Performance

World Health Organization
What is the minimum amount of data that will have to be recorded on reporting forms at community level?
Minimum Data Requirements:

Community Level

- Age group and sex of each person treated
- Date of PC
- Place of PC (school, village, etc)
- Name of person administering the drug
- Name(s) of drug(s) administered and quantities
- Drug registers should be adapted to the local context/language
### Module 6. Monitoring and Evaluation (M&E)

**Session 2. Measuring NTDP Performance**

<table>
<thead>
<tr>
<th>District:</th>
<th>Health unit:</th>
<th>Town/Village:</th>
<th>Form Number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Region/Province:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Tally sheet for recording preventive chemotherapy treatments at drug distribution points:

- [ ] praziquantel
- [ ] albendazole/mebendazole
- [ ] ivermectin
- [ ] diethylcarbamazine
- [ ] azithromycin

#### Module 6. Monitoring and Evaluation (M&E)

**Session 2. Measuring NTDP Performance**

<table>
<thead>
<tr>
<th>SEX</th>
<th>1–4 years</th>
<th>5–14 years</th>
<th>≥16 years</th>
<th>1–4 years</th>
<th>5–14 years</th>
<th>≥16 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE GROUP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| TOTAL treated, by age group |          |            |           |           |            |           |
|                            |          |            |           |           |            |           |
| TOTAL treated, by sex      |           |            |           |           |            |           |
| TOTAL TREATED: males + females |       |          |            |           |           |            |

Community drug distributor: ____________________________  Supervisor: ____________________________  Date: ____________________________
### Module 6. Monitoring and Evaluation (M&E)

**Session 2. Measuring NTDP Performance**

<table>
<thead>
<tr>
<th>No.</th>
<th>INDIVIDUAL IDENTIFICATION</th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>ROUND No:</th>
<th>Drug 1:</th>
<th>Drug 2:</th>
<th>Reasons for non-treatment* (Enter code as given below)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Name</td>
<td>Address</td>
<td></td>
<td></td>
<td>Drug 1:</td>
<td>Drug 2:</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: Details for each column are to be filled in according to the guidelines provided in the training course materials.*
Minimum Data Requirements: District Level

- District name, NTDs targeted, drugs used
- # of drugs received, number used, and number remaining
- List of facilities that have submitted data
- Date of receipt of data
- # targeted at each facility
- # treated at each facility by age-group and sex
Calculations: District level

- Data completeness
- Data timeliness
- District level programmatic coverage:
  - Total
  - Disaggregated by sex
  - Disaggregated by each age-group
### Monitoring drug coverage for preventive chemotherapy. WHO

**ANNEX II.3 Form for data compilation at the district level – Example of a tabulated summary**

**FORM FOR SUMMARIZING PREVENTIVE CHEMOTHERAPY TREATMENTS**

- **Person reporting:**
- **Administrative level:**
- **Round of treatment:** Round 1 or Round 2
- **Reporting date:**

**Objective:**

- **Drug used:**
- **Number of batches received:**
- **Number of batches used:**
- **Number of batches remaining:**

**Total number of reports reported:**

**Total number of reports received:**

### Module 6. Monitoring and Evaluation (M&E)

**Session 2. Measuring NTDP Performance**
What action should be taken by district level manager?
Data Management at District Level

- Follow up on missing reports.
- Follow up where program coverage is very low or >100% to identify problems, check data quality and complete data in a timely fashion.
- Report to next level – region/national.
Data Quality Control

• Which NTDs were targeted? And what drugs were used?
• How many drug combinations were used?
• How many times was PC administered in 1 year?
• How was the data collected?
• Is the data gender disaggregated? (if not, it should be)
• What type of indicators were computed?
• What types of coverage where observed?
• Was there very low/very high coverages? If so, what were the reasons?
• What was the completeness and the timeliness of the data?
• How was the data forwarded to the next supervisory level?
• Was feedback received at field level after submission to supervisory level?
• Was data shared between different implementing programs, agencies?
• Challenges experienced and suggestions as to how these could be addressed
Examples of Data Quality Concerns and Possible Causes

<table>
<thead>
<tr>
<th>Data quality concern</th>
<th>Possible cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage &gt;100%</td>
<td></td>
</tr>
<tr>
<td>Large variations in total number of PC doses used from year to year at the same reporting level</td>
<td></td>
</tr>
<tr>
<td>Large discrepancy between PC doses distributed from stores and number of doses reported as ingested during the same treatment round</td>
<td></td>
</tr>
</tbody>
</table>

* Refers to the use of dose poles for determining the correct dose of certain drugs. PC – preventive chemotherapy.
Post Event Coverage Survey (PECS)

- Have you participated in a PECS?
- Why was the PECS done?
- Where was the PECS done?
- How was it done?
- By whom was it done?
- Was there integration with other programs?
- What caliber of personnel conducted the PECS?
- What were the main challenges of the validation?
- What were the findings/observation from the PECS?
- What conclusions were drawn with regard to data quality?
- Was the PECS disseminated? If so, how and by whom?
PECS Compared to Reported Coverage
Reported drug coverage = monitoring, PECS coverage = evaluation
Methods for Validating Reported Coverage/data

During MDA

1. Concordance monitoring
   - recounting done by supervisors.

2. Rapid Coverage Assessment
   - Protocol is under development (2015).
Methods for Validating Reported Coverage/data

After MDA

1. Coverage Evaluation
   - Protocol is under development (2015).

2. Data Quality Assessment
   - Data Quality Assessment (DQA): Once every 3 to 5 years, before re-planning for next national NTD Master plan. Conducted with independent assessors.
What do you think are the key messages from this session?
Key Messages

• Performance indicators measure the effectiveness of activities.
• Indicators measured should be important, useful, and feasible, resulting in improved quality of activities.
• Monitoring coverage is THE KEY performance indicator.
• Very low or very high coverage should be further investigated and understood by the NTDP.
• Action should be initiated in response to M&E findings.
• It is important to ensure quality of the data.